Compare CRBP & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBP | AOMR |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 210.5M |
| IPO Year | 2014 | 2019 |
| Metric | CRBP | AOMR |
|---|---|---|
| Price | $9.05 | $8.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $45.50 | $11.08 |
| AVG Volume (30 Days) | ★ 419.1K | 129.4K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.18% |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | $1.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $7.12 | $7.96 |
| 52 Week High | $20.56 | $10.14 |
| Indicator | CRBP | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | N/A |
| Support Level | $7.86 | N/A |
| Resistance Level | $9.73 | N/A |
| Average True Range (ATR) | 0.44 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.59 | 0.00 |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.